Cumulative 2-year NRM and relative 95% CI according to HCT-CI score and condition
| Predictor . | HCT-CI score . | P . | c-statistics . | ||
|---|---|---|---|---|---|
| 0 . | 1-2 . | ≥ 3 . | |||
| Related donor | 8.9 (6.2-12.3) | 20.8* (13.7-28.9) | 22.0† (14.2-31.0) | < .001 | 0.63 |
| Unrelated donor | 22.4 (18.3-26.6) | 24.9 (18.2-32.2) | 27.3 (19.6-34.9) | .23 | 0.53 |
| BM | 20.2 (15.2-25.8) | 17.7 (9.8-27.3) | 26.29 (16.58-37.02) | .23 | 0.53 |
| PBSCs | 15.5 (12.4-18.3) | 26.9* (21.4-32.9) | 32.3† (25.70-39.10) | < .001 | 0.61 |
| RIC | 17.9 (13.4-22.9) | 29.2* (21.2-37.6) | 33.1† (25.2-41.0) | < .001 | 0.59 |
| Myeloablative conditioning | 16.0 (12.9-19.2) | 20.9 (15.1-27.0) | 29.6† (21.6-37.3) | < .001 | 0.58 |
| Disease | |||||
| Acute leukemia | 15.7 (12.4-19.4) | 18.3 (13.0-24.4) | 22.0 (15.4-29.1) | .12 | 0.54 |
| AML | 13.4 (10.2-16.9) | 13.7 (9.0-19.4) | 20.7 (14.4-27.8) | .08 | 0.54 |
| AML, first remission | 9.1 (5.9-13.1) | 11.4 (6.2-18.3) | 19.4 (10.9-29.7) | .03 | 0.59 |
| Multiple myeloma | 21.5 (13.6-30.7) | 34.3 (18.2-51.2) | 26.1 (9.0-45.9) | .31 | 0.57 |
| Lymphoma (Hodgkin and non-Hodgkin) | 12.3 (8.2-17.3) | 23.4* (14.5-33.4) | 30.1† (20.0-40.9) | < .001 | 0.66 |
| MDS | 18.9 (12.7-26.1) | 30.6* (19.6-42.4) | 47.4† (34.1-59.7) | < .001 | 0.64 |
| Chronic myeloid leukemia | 16.9 (8.2-28.3) | 15.3 (2.1-39.9) | 42.8 (7.1-76.1) | .22 | 0.60 |
| All diseases | 14.7 (12.7-16.8) | 21.3* (17.6-25.2) | 27.3 (22.9-31.8) | < .001 | 0.60 |
| Predictor . | HCT-CI score . | P . | c-statistics . | ||
|---|---|---|---|---|---|
| 0 . | 1-2 . | ≥ 3 . | |||
| Related donor | 8.9 (6.2-12.3) | 20.8* (13.7-28.9) | 22.0† (14.2-31.0) | < .001 | 0.63 |
| Unrelated donor | 22.4 (18.3-26.6) | 24.9 (18.2-32.2) | 27.3 (19.6-34.9) | .23 | 0.53 |
| BM | 20.2 (15.2-25.8) | 17.7 (9.8-27.3) | 26.29 (16.58-37.02) | .23 | 0.53 |
| PBSCs | 15.5 (12.4-18.3) | 26.9* (21.4-32.9) | 32.3† (25.70-39.10) | < .001 | 0.61 |
| RIC | 17.9 (13.4-22.9) | 29.2* (21.2-37.6) | 33.1† (25.2-41.0) | < .001 | 0.59 |
| Myeloablative conditioning | 16.0 (12.9-19.2) | 20.9 (15.1-27.0) | 29.6† (21.6-37.3) | < .001 | 0.58 |
| Disease | |||||
| Acute leukemia | 15.7 (12.4-19.4) | 18.3 (13.0-24.4) | 22.0 (15.4-29.1) | .12 | 0.54 |
| AML | 13.4 (10.2-16.9) | 13.7 (9.0-19.4) | 20.7 (14.4-27.8) | .08 | 0.54 |
| AML, first remission | 9.1 (5.9-13.1) | 11.4 (6.2-18.3) | 19.4 (10.9-29.7) | .03 | 0.59 |
| Multiple myeloma | 21.5 (13.6-30.7) | 34.3 (18.2-51.2) | 26.1 (9.0-45.9) | .31 | 0.57 |
| Lymphoma (Hodgkin and non-Hodgkin) | 12.3 (8.2-17.3) | 23.4* (14.5-33.4) | 30.1† (20.0-40.9) | < .001 | 0.66 |
| MDS | 18.9 (12.7-26.1) | 30.6* (19.6-42.4) | 47.4† (34.1-59.7) | < .001 | 0.64 |
| Chronic myeloid leukemia | 16.9 (8.2-28.3) | 15.3 (2.1-39.9) | 42.8 (7.1-76.1) | .22 | 0.60 |
| All diseases | 14.7 (12.7-16.8) | 21.3* (17.6-25.2) | 27.3 (22.9-31.8) | < .001 | 0.60 |